Pharmaceutical Biology has retracted a 2012 paper by a group of liver researchers from China after the discovery of an error that evidently invalidated the results in the paper.
The article, “Antifibrotic effects of protocatechuic aldehyde on experimental liver fibrosis,” purported to show that
protocatechuic aldehyde, the major degradation of phenolic acids … has potentially conferring antifibrogenic effects.
The editors and publisher would like to inform readers the following article has been retracted from publication in Pharmaceutical Biology:
Li CM, Jiang WL, Zhu HB, Hou J. Antifibrotic effects of protocatechuic aldehyde on experimental liver fibrosis. Pharm Biol. 2012; 50(4): 413–419. (doi: 10.3109/13880209.2011.608193).
Following publication of this article, an error has been identified and upon further investigation of the effects of protocatechuic aldehyde on liver fibrosis, the results indicated protocatechuic aldehyde has no significant effect on liver fibrosis.
The authors have been fully co-operative and offer their sincerest apologies to the readers and the publishers of the Pharmaceutical Biology article and accept the retraction of this paper.
Pharmaceutical Biology published this article in good faith, and on the basis of signed statements of the corresponding author regarding the originality and ethical reliability of their work. The article is withdrawn from all print and electronic editions.